Status:

RECRUITING

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

Lead Sponsor:

University of Arizona

Collaborating Sponsors:

Sidney R. Baer, Jr. Foundation

Conditions:

Schizophrenia

Eligibility:

All Genders

18-40 years

Phase:

PHASE1

Brief Summary

Schizophrenia is a severe psychotic illness of unknown cause that affects 1% of the population worldwide. Currently, there is no diagnostic test for schizophrenia. Instead, the diagnosis is typically ...

Detailed Description

The overall objective of the study is to test the hypothesis that patients with schizophrenia will have a heightened tolerance to the sedating effects of antipsychotic medications, which will be refle...

Eligibility Criteria

Inclusion

  • Inclusion Criteria Healthy Control
  • Be between 18 and 40 years of age
  • Be able to understand English
  • Have no history of psychosis
  • Have no history of sleep apnea, heart condition or seizure
  • Have no known drug allergies
  • The ability to swallow a pill
  • Exclusion Criteria Healthy control
  • Refuse to sign the consent form
  • Drink caffeine or alcohol within 24 hours of the study
  • Have the EKG readout report borderline or abnormal ECG
  • Have the 12 panel urine drug screen show a positive result
  • Be pregnant
  • Inclusion Criteria Schizophrenic subject
  • Be between 18 and 40 years of age
  • Be able to understand English
  • Have been diagnosed with a Schizophrenia Spectrum or other psychotic disorder
  • Belong to one of three groups:
  • Never medicated patients with a first episode of psychosis
  • Have not received long acting injectable (depot) antipsychotic in previous 6 months
  • Have not received oral antipsychotic (or antidepressant that has serotonergic action) in previous 2 weeks
  • Have no history of sleep apnea, heart condition or seizure
  • Have no known drug allergies
  • Be able to swallow a pill
  • Healthy as determined by the enrolling physician(s)
  • Exclusion Criteria Schizophrenic subject
  • Refuse to sign the consent form
  • Drink caffeine or alcohol within 24 hours of the study
  • Have the EKG readout report borderline or abnormal ECG
  • Have the 12 panel urine drug screen show a positive result
  • Be pregnant

Exclusion

    Key Trial Info

    Start Date :

    November 20 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    February 10 2026

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT03781115

    Start Date

    November 20 2017

    End Date

    February 10 2026

    Last Update

    June 3 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Banner University Medical Center

    Phoenix, Arizona, United States, 85006